Medicine
Vyndaqel 20 mg capsule
Vyndaqel 20 mg capsule is a prescription medicine containing Tafamidis for oral use, marketed by Pfizer Laboratories, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store VYNDAQEL and VYNDAMAX at controlled room temperature 20°C to 25°C (68°F…
Key facts
- Active ingredient (INN)
- Tafamidis
- Brand
- Vyndaqel
- Strength
- 20 mg
- Dosage form
- Capsule
- Route
- Oral
- Packs
- 4 cartons
- Marketing authorisation holder
- Pfizer Laboratories
- Manufacturer
- Pfizer Laboratories
- Origin register
- US FDA, United States
- Storage
- Store VYNDAQEL and VYNDAMAX at controlled room temperature 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N07XX08 Tafamidis
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 16 May 2019
- Identifiers
- RxCUI 2168534, 2168540, 2168542 +1DailyMed set ID 1b4121ee-a733-4456-a917-be2603477839NDC 0069-1975Application NDA211996
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 4 carton in 1 carton / 30 blister pack in 1 carton / 1 capsule, liquid filled in 1 blister pack | 0069-1975-40 | Pfizer Laboratories | 16 May 2019 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Tafamidis
Clinical summary
Tafamidis is a prescription medicine indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. It is available as capsules for oral use. MedsAcross supplies Tafamidis for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about TafamidisFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Vyndaqel prescribing information (Pfizer Laboratories) · U.S. National Library of Medicine, DailyMed
- Vyndaqel: European public assessment report (EPAR) · European Medicines Agency
- Tafamidis Accord: European public assessment report (EPAR) · European Medicines Agency
Need Vyndaqel 20 mg capsule for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.